Cerus (NASDAQ:CERS) Shares Pass Above 200-Day Moving Average – Should You Sell?

Shares of Cerus Corporation (NASDAQ:CERS) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.76 and traded as high as $2.58. Cerus shares last traded at $2.56, with a volume of 1,788,851 shares.

Analysts Set New Price Targets

CERS has been the topic of a number of research reports. Wall Street Zen upgraded shares of Cerus from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. TD Cowen reissued a “buy” rating on shares of Cerus in a research report on Monday, January 12th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Cerus presently has a consensus rating of “Hold” and an average target price of $4.00.

Cerus Trading Up 3.6%

The stock’s 50 day moving average is $2.26 and its 200-day moving average is $1.76. The company has a market cap of $491.75 million, a P/E ratio of -32.00 and a beta of 1.52. The company has a current ratio of 1.89, a quick ratio of 1.29 and a debt-to-equity ratio of 0.78.

Institutional Trading of Cerus

Several institutional investors have recently added to or reduced their stakes in the business. Cibc World Markets Corp bought a new position in shares of Cerus during the fourth quarter valued at $25,000. MML Investors Services LLC bought a new position in Cerus during the 4th quarter valued at about $37,000. Caitong International Asset Management Co. Ltd lifted its stake in Cerus by 68.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 18,712 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 7,603 shares during the period. Bingham Private Wealth LLC purchased a new stake in shares of Cerus during the 4th quarter valued at about $40,000. Finally, CIBC Bancorp USA Inc. bought a new stake in shares of Cerus in the third quarter worth approximately $31,000. 78.37% of the stock is currently owned by hedge funds and other institutional investors.

About Cerus

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.